Division of Pediatric Hematology/Oncology

Clinical Trials

Central Nervous System

ACNS0121: Phase II— Trial of conformal radiation treatment for pediatric patients with localized ependymoma, chemotherapy prior to second surgery for incompletely resected ependymoma and observations for completely resected, differentiated, supratentorial ependymoma
Principal investigator: Cindy Schwartz, MD

ACNS0112: Phase II— Study to assess the ability of neoadjuvant chemotherapy with or without second look surgery to eliminate all measurable disease prior to radiotherapy for nongerminomatous germ-cell tumor
Principal investigator: Cindy Schwartz, MD

ACNS0223: Phase II— Pilot study using Carboplatin, Vincristine and Temozolomide for children ten years or younger with progressive, symptomatic low-grade gliomas
Principal investigator: Cindy Schwartz, MD

ACNS02B1: Phase N/A — Pre-clinical pharmacology in surgical brain tumor specimens
Principal investigator: Cindy Schwartz, MD

ACNS02B3: Phase N/A — A Children's Oncology Group protocol for collecting and banking pediatric brain tumor research specimens
Principal investigator: Cindy Schwartz, MD

ACNS0331: Phase III — A double randomized trial evaluating limited target volume boost irradiation and reduced dose craniospinal radiotherapy 18.00 Gy and chemotherapy in children with newly diagnosed standard risk medulloblastoma
Principal investigator: Cindy Schwartz, MD

ACNS0423: Phase III — Current radiation and Temozolomide followed by Temozolomide and Lomustine in the treatment of high-grade gliomas
Principal investigator: Cindy Schwartz, MD

DFCI 01-279: Phase II Pilot — Study of Thalidomide with Temozolomide in patients with relapsed or progressive brain tumors or those with recurrent neuroblastomas
Principal investigators: Cindy Schwartz, MD and Peter Manley, MD

DFCI 199-310: Phase Pilot — Effects of cranial-spinal radiation therapy on abdominal organ function
Principal investigators: Cindy Schwartz, MD and Peter Manley, MD

For more information about these clincial trials and how to participate, please call 401-444-HOPE (4673). For general information about clinical trials please visit the National Cancer Institute.